Conclusions
liver stiffness, neurotoxic
MINOR
In conclusion we observed minor changes in CSF and hepatic biomarkers and no change in IMT after 24 weeks of switch to a less neurotoxic regimen that included emtricitabine, darunavir/cobicistat and maraviroc. Some changes were potentially deleterious, as we observed rising in neopterin and NFL, while others appear promising, since we registered lower ptau, stiffness and APRI values in the intervention arm. We could not observe a strict relationship between CNS and liver function. A more extensive investigation regarding the gut-brain axis and other markers analyzing the role of liver stiffness, inflammatory and neuromarkers should be implemented in larger cohorts to better characterize this plausible still unproven hypothesis.